Navigation Links
Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment
Date:7/23/2008

under Section 505(b)(2)".

Dr. Amir Pelleg, Duska's President and Chief Scientific Officer, stated, "I expect that the Special Protocol Assessment by the FDA would facilitate the completion of the clinical development of ATPace(TM) in a timely fashion".

About ATPace(TM)

ATPace(TM) (adenosine triphosphate injection) is a proposed product for the termination of paroxysmal supraventricular tachycardia (PSVT). The bradycardic effect of ATP, in particular its blockade of atrio-ventricular nodal (AVN) conduction, has been shown to effectively terminate re-entrant PSVT involving the AV node. Adenosine is the only approved competition in the U.S. Duska believes that the initial dose of ATPace(TM) will be significantly more efficacious than the initial labeled dose of adenosine in terminating PSVT. While ATP and adenosine both inhibit AVN conduction, ATPace(TM) is believed to have a second mechanism of action to stimulate vagally-mediated suppression of AVN conduction. Injectable formulations of ATP have been approved in Europe for over 50 years as safe and efficacious treatments for PSVT. Duska has completed Phase 1 and 2 clinical trials in diagnosing bradycardia, and has acquired more than 1,000 patients records from other clinical trials. Duska has met with the FDA to ascertain which additional requirements might be necessary for marketing approval of ATPace(TM). Duska plans a 505(b)(2) NDA filing route for approval.

About Duska Therapeutics, Inc.

Duska Therapeutics, Inc. (Duska) is a specialty pharmaceutical company that develops new cardiovascular and pulmonary medicines based upon the emerging new pharmacology of adenosine triphosphate (ATP) and nitric oxide (NO). These two molecules play critical roles in cellular metabolism and signal transduction, the manipulation of which by several pharmaceuticals constitute novel therapeutic modalities for the treatment of major cardiovascular disorders. Duska is developing a portfolio of investi
'/>"/>

SOURCE Duska Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Duska Therapeutics Obtains Standard & Poors Listing
2. Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics
3. CV Therapeutics to Announce 2008 Second Quarter Financial Results on Thursday, July 31, 2008
4. Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008
5. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
6. Northwest Biotherapeutics to Present at Next Generation Vaccine Conference
7. Organizational Changes at Silence Therapeutics
8. Genzyme Corporation and PTC Therapeutics Announce Collaboration on Small Molecule for Genetic Diseases
9. Arno Therapeutics Announces New Ticker Symbol
10. Lorus Therapeutics Receives $600 Thousand From Escrow Account
11. Silence Therapeutics Announces Successful Opposition of Glover Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... Irvine, CA (PRWEB) April 16, 2015 ... in the Buzz of BIO Contest for ... Industry Organization (BIO), the 2015 BIO International Convention will ... in Philadelphia, Pennsylvania. During the Buzz of BIO contest, ... like to see present at the conference. The community ...
(Date:4/16/2015)... 2015 Regis Technologies looks forward to ... Cancer Research (AACR) annual meeting. Regis will exhibit at ... Saturday, April 18, in Philadelphia and running through April ... of the oldest and largest organization focused on cancer ... and partners with survivors to promote awareness and research ...
(Date:4/16/2015)... April 16, 2015 OncoTAb, ... Charlotte (UNC Charlotte) spin-out company, announced today the ... Ph.D., M.D., as Chief Operating Officer (COO). Cooper ... experience in developing clinical diagnostic and biotechnology platforms ... disease. , Cooper’s extensive career transcends the field ...
(Date:4/16/2015)... 2015  In recognition of World Hemophilia Day, Biogen ... to illuminate more than 15 prominent landmarks red throughout ... Zakim Bridge and Prudential Tower, Chicago,s ... Mercedes-Benz Superdome and Denver,s Coors ... April 17, and coincide with hemophilia community events in a ...
Breaking Biology Technology:Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 2Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 3Regis Technologies Joins American Association for Cancer Research Annual Meeting 2OncoTAb Names Dr. David L. Cooper as COO 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 3Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 4
... by Stent Manufacturers Expected to ... - Witness Live Case Examples of Advanced Practices by Leading, Interventionalists, Broadcast from ... the Role of IVUS in Improving Stent, Results. - See How Many of the ... ...
... 22 Agendia BV, a,world leader in the rapidly ... Chief Research Officer Laura van ,t Veer has,received a ... Ribbon Breast Cancer Research Foundation. The Pink Ribbon ... 151 international breast cancer researchers with a total value ...
... CAMBRIDGE, Mass., Oct. 22 Genzyme Corp.,(Nasdaq: ... and Drug Administration,has granted marketing approval for Renvela(TM) ... patients with chronic kidney disease on,dialysis. Renvela is ... phosphate binder in the United States. "Since ...
Cached Biology Technology:Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated 2Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated 3Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated 4Agendia BV Announces That its Chief Research Officer Laura van 't Veer has Received a 2007 Breast Cancer Research Foundation Award 2FDA Approves Genzyme's Renvela(TM) for Dialysis Patients 2FDA Approves Genzyme's Renvela(TM) for Dialysis Patients 3FDA Approves Genzyme's Renvela(TM) for Dialysis Patients 4FDA Approves Genzyme's Renvela(TM) for Dialysis Patients 5
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... with critical security-authentication needs, today announced the beginning of ... (FFD) solution. The company, based in ... at the three-day Connect:ID Expo, which began here today ... NexID said version 2.0 of its SDK boosts the ...
(Date:3/23/2015)...   HOYOS Labs , a leading global authentication ... the Company will demonstrate multiple biometrics-based technologies under its ... Connect:ID on March 23 through 25, 2015, in ... the IEEE Biometric Open Protocol Standard; free biometrics-based consumer ... control system. BOPS was invented by HOYOS Labs and ...
(Date:3/20/2015)... , Mar. 20, 2015 Research and Markets ... addition of the "India Sensors Market Forecast ... The sensor market is projected to ... Consumer electronics, automotive, industrial and healthcare ... in the country. In addition, adoption of MEMS ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3
... at Loyola University Chicago Stritch School of Medicine have ... Institutes of Health to study vitamin D deficiency in ... relation between low vitamin D levels and risks for ... Evidence from numerous previous studies is "inconclusive and needs ...
... WEST LAFAYETTE, Ind. - A Purdue University researcher has ... might lead to improvements in that and other crops. ... landscape architecture, wanted to understand the relationship between natural ... plant architecture, specifically plant height. Schulz said corn could ...
... at the University of North Carolina at Chapel Hill have ... different viruses in an effort to create the ultimate vehicle ... investigators found no side effects from using a "chimeric" virus ... patients with muscular dystrophy. "This trial demonstrates that gene ...
Cached Biology News:Loyola receives NIH grant to study vitamin D deficiency in African populations 2Stronger corn? Take it off steroids, make it all female 2Stronger corn? Take it off steroids, make it all female 3Clinical trial for muscular dystrophy demonstrates safety of customized gene therapy 2